207 related articles for article (PubMed ID: 8962181)
1. Malononitrilamides inhibit the development of various murine graft-vs-host diseases.
Schorlemmer HU; Kurrle R; Bartlett RR
Transplant Proc; 1996 Dec; 28(6):3043-7. PubMed ID: 8962181
[No Abstract] [Full Text] [Related]
2. The new immunosuppressants, the malononitrilamides MNA 279 and MNA 715, inhibit various graft-vs.-host diseases (GvHD) in rodents.
Schorlemmer HU; Kurrle R; Bartlett RR
Drugs Exp Clin Res; 1997; 23(5-6):167-73. PubMed ID: 9515226
[TBL] [Abstract][Full Text] [Related]
3. Malononitrilamides prevent the development of murine systemic lupus erythematosus-like diseases in BDF1 hybrid mice and MRL/lpr autoimmune mice.
Schorlemmer HU; Brendel S; Bartlett RR
Transplant Proc; 1996 Dec; 28(6):3040-2. PubMed ID: 8962180
[No Abstract] [Full Text] [Related]
4. Analogues of leflunomide's primary metabolite, the malononitrilamides, prevent the development of graft-versus-host disease.
Schorlemmer HU; Bartlett RR; Kurrle R
Transplant Proc; 1997; 29(1-2):1298-301. PubMed ID: 9123315
[No Abstract] [Full Text] [Related]
5. Prevention of the development of murine systemic lupus erythematosus (SLE)-like diseases by the malononitrilamides MNA 279 and MNA 715.
Schorlemmer HU; Bartlett RR
Inflamm Res; 1997 Aug; 46 Suppl 2():S167-8. PubMed ID: 9297564
[No Abstract] [Full Text] [Related]
6. Various graft vs. host diseases (GvHD) in rodents can be prevented and treated by malononitrilamides (MNAs).
Schorlemmer HU; Kurrle R; Bartlett RR
Inflamm Res; 1997 Aug; 46 Suppl 2():S165-6. PubMed ID: 9297563
[No Abstract] [Full Text] [Related]
7. Modulation of immunoglobulin dysregulation in graft versus host-and systemic lupus erythematosus-like diseases by malononitrilamides.
Schorlemmer HU; Bartlett RR
Transplant Proc; 1998 Dec; 30(8):4153-5. PubMed ID: 9865331
[No Abstract] [Full Text] [Related]
8. Inhibition of alloreactivity in the popliteal lymph node assay by malononitrilamides.
Schorlemmer HU; Bartlett RR; Kurrle R
Transplant Proc; 1998 Jun; 30(4):968-70. PubMed ID: 9636391
[No Abstract] [Full Text] [Related]
9. Acute skin graft rejection can be prevented and treated in rat models by malononitrilamides.
Schorlemmer HU; Schwab W; Ruuth E; Kurrle R
Transplant Proc; 1996 Dec; 28(6):3048-50. PubMed ID: 8962182
[No Abstract] [Full Text] [Related]
10. Control of mouse-to-rat skin xenograft rejection by malononitrilamides.
Schorlemmer HU; Kurrle R
Transplant Proc; 1996 Dec; 28(6):3037-9. PubMed ID: 8962179
[No Abstract] [Full Text] [Related]
11. Rapamycin suppression of host-versus-graft and graft-versus-host disease in MHC-mismatched rats.
Fabian MA; Denning SM; Bollinger RR
Transplant Proc; 1992 Jun; 24(3):1174. PubMed ID: 1604575
[No Abstract] [Full Text] [Related]
12. FTY720, a novel immunosuppressant, possessing unique mechanisms. IV. Prevention of graft versus host reactions in rats.
Masubuchi Y; Kawaguchi T; Ohtsuki M; Suzuki C; Amano Y; Hoshino Y; Chiba K
Transplant Proc; 1996 Apr; 28(2):1064-5. PubMed ID: 8623228
[No Abstract] [Full Text] [Related]
13. The effect of endotoxin of Escherichia coli on the graft-versus-host reaction in mice. II. Non-H-2 systems.
Skopińska E
Arch Immunol Ther Exp (Warsz); 1974; 22(3):301-4. PubMed ID: 4151941
[No Abstract] [Full Text] [Related]
14. Immunosuppressive activity of FTY720, sphingosine 1-phosphate receptor agonist: II. Effect of FTY720 and FTY720-phosphate on host-versus-graft and graft-versus-host reaction in mice.
Kataoka H; Ohtsuki M; Shimano K; Mochizuki S; Oshita K; Murata M; Sugahara K; Sato N; Hoshino Y; Chiba K
Transplant Proc; 2005; 37(1):107-9. PubMed ID: 15808562
[No Abstract] [Full Text] [Related]
15. The flavonoid Kaempferol suppresses the graft-versus-host reaction by inhibiting type 1 cytokine production and CD8+ T cell engraftment.
Okamoto I; Iwaki K; Koya-Miyata S; Tanimoto T; Kohno K; Ikeda M; Kurimoto M
Clin Immunol; 2002 May; 103(2):132-44. PubMed ID: 12027418
[TBL] [Abstract][Full Text] [Related]
16. [Inhibition of the regional graft vs. host reaction in F1 mice preliminarily treated intrahepatically with semiallogeneic lymphocytes].
Divanian Kh
Eksp Med Morfol; 1986; 25(4):43-7. PubMed ID: 3816649
[No Abstract] [Full Text] [Related]
17. The effect of Escherichia coli endotoxin on the graft-versus-host reaction in mice. 3. Runt disease in newborns.
Skopińska E
Arch Immunol Ther Exp (Warsz); 1974; 22(3):305-8. PubMed ID: 4151942
[No Abstract] [Full Text] [Related]
18. [Development of the graft versus host reaction and its influence on pregnancy in mice following heparin administration].
Fedosov EA
Biull Eksp Biol Med; 1977 Mar; 83(3):312-5. PubMed ID: 15685
[TBL] [Abstract][Full Text] [Related]
19. LF 08-0299 protects murine recipients of minor antigen disparate donor bone marrow from lethal graft-versus-host disease.
Bruley-Rosset M; Churaqui E; Annat J; Dutartre P
Transplant Proc; 1996 Dec; 28(6):3114-6. PubMed ID: 8962208
[No Abstract] [Full Text] [Related]
20. Immunosuppressive power and limitations of FK 506 for prevention and treatment of graft-vs-host disease after small bowel transplantation.
Platz KP; Mueller AR; Langrehr JM; Neuhaus P; Schraut WH
Transplant Proc; 1996 Oct; 28(5):2523-4. PubMed ID: 8907933
[No Abstract] [Full Text] [Related]
[Next] [New Search]
